Renovaro Biosciences Stock Today
| RENB Stock | 0.76 0.01 1.33% |
PerformanceVery Weak
| Odds Of DistressLow
|
Renovaro Biosciences is trading at 0.76 as of the 20th of March 2025, a 1.33 percent increase since the beginning of the trading day. The stock's open price was 0.75. Renovaro Biosciences has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Moving against Renovaro Stock
| 0.36 | MDWD | Mediwound Downward Rally | PairCorr |
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Renovaro Stock Highlights
| CEO Director | David Weinstein |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) |
Renovaro Biosciences (RENB) is traded on NASDAQ Exchange in USA. It is located in 2080 Century Park East, Los Angeles, CA, United States, 90067 and employs 25 people. Renovaro Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 121.5 M. Renovaro Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 162.39 M outstanding shares of which 6.33 M shares are at this time shorted by private and institutional investors with about 2.82 trading days to cover.
Renovaro Biosciences generates negative cash flow from operations
Check Renovaro Biosciences Probability Of Bankruptcy
Ownership AllocationRenovaro Biosciences owns a total of 162.39 Million outstanding shares. Renovaro Biosciences has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Renovaro Ownership Details
Renovaro Biosciences Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Renovaro Biosciences market risk premium is the additional return an investor will receive from holding Renovaro Biosciences long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | 0.276 | |||
| Treynor Ratio | 0.9799 |
Renovaro Stock Against Markets
Renovaro Biosciences Corporate Management
| Greg Duczynski | Senior Operations | Profile | |
| Simon Tarsh | Interim Officer | Profile | |
| Nathen CPA | Chief Officer | Profile | |
| Francois MSc | Executive Development | Profile | |
| Evelyn DAn | Consultant | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renovaro Biosciences. If investors know Renovaro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renovaro Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Renovaro Biosciences is measured differently than its book value, which is the value of Renovaro that is recorded on the company's balance sheet. Investors also form their own opinion of Renovaro Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Renovaro Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renovaro Biosciences' market value can be influenced by many factors that don't directly affect Renovaro Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renovaro Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Renovaro Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renovaro Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.